Related Experiment Video
Updated: Jun 28, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
[Annual progress of immunotherapy for tuberculosis in 2023]
1Department of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai Clinic and Research Center of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai 200433, China.
Immunotherapy is crucial for treating tuberculosis (TB), a chronic infectious disease. Recent research highlights host-targeted therapies and vaccines as promising new avenues for combating drug-resistant TB.
Area of Science:
- Immunology
- Infectious Diseases
- Microbiology
Context:
- Tuberculosis (TB) is a chronic infectious disease intricately linked to immune system regulation and function.
- Immunotherapy presents a vital strategy for enhancing TB treatment efficacy and controlling disease transmission.
- Recent advancements (Oct 2022-Sep 2023) show a surge in global research on TB immunotherapy.
Purpose:
- To review the current landscape of tuberculosis immunotherapy research.
- To identify emerging trends and opportunities in TB treatment.
- To explore novel therapeutic strategies for drug-resistant TB.
Summary:
- Immunotherapy plays a key role in the comprehensive management of tuberculosis.
- Increased global research activity from October 2022 to September 2023 offers new hope for treating multidrug-resistant and extensively drug-resistant TB.
- Host-targeted therapy and therapeutic vaccines represent promising future directions for adjuvant TB therapy.
Impact:
- Immunotherapy research provides new avenues for tackling challenging TB cases, including drug-resistant strains.
- Advancements in host-targeted therapies and vaccines could significantly improve patient outcomes.
- This research contributes to the global effort to control and eradicate tuberculosis through innovative treatment modalities.
More Related Videos
10:04Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
06:26Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Tumor Immunotherapy